Cargando…

Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden

SUMMARY: Romosozumab is a novel bone-building drug that reduces fracture risk. This health economic analysis indicates that sequential romosozumab-to-alendronate can be a cost-effective treatment option for postmenopausal women with severe osteoporosis at high risk of fracture. PURPOSE: To estimate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Söreskog, E., Lindberg, I., Kanis, J.A., Åkesson, K.E., Willems, D., Lorentzon, M., Ström, O., Berling, P., Borgström, F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer London 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7929944/ https://www.ncbi.nlm.nih.gov/pubmed/33409591 http://dx.doi.org/10.1007/s00198-020-05780-8

Ejemplares similares

A novel economic framework to assess the cost-effectiveness of bone-forming agents in the prevention of fractures in patients with osteoporosis
por: Söreskog, E., et al.
Publicado: (2021)

Denosumab versus romosozumab for postmenopausal osteoporosis treatment
por: Kobayakawa, Tomonori, et al.
Publicado: (2021)

Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada
por: Goeree, Ron, et al.
Publicado: (2022)

Romosozumab for osteoporosis
Publicado: (2021)

Romosozumab for the treatment of osteoporosis
por: McClung, Michael R.
Publicado: (2018)

Romosozumab efficacy on fracture outcomes is greater in patients at high baseline fracture risk: a post hoc analysis of the first year of the frame study
por: McCloskey, E. V., et al.
Publicado: (2021)

The Effect of 1 Year of Romosozumab on the Incidence of Clinical Vertebral Fractures in Postmenopausal Women With Osteoporosis: Results From the FRAME Study
por: Geusens, Piet, et al.
Publicado: (2019)

OR13-05 Romosozumab Treatment Lowers the Incidence of New Vertebral Fractures Across All Fracture Severity Grades Among Postmenopausal Women with Osteoporosis
por: Feldman, Robert, et al.
Publicado: (2020)

Romosozumab in osteoporosis: yesterday, today and tomorrow
por: Wu, Dong, et al.
Publicado: (2023)

Effect of Romosozumab on Trabecular Bone Score Compared to Anti-Resorptive Agents in Postmenopausal Women with Osteoporosis
por: Jeong, Chaiho, et al.
Publicado: (2021)

Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild‐to‐Moderate Chronic Kidney Disease
por: Miller, Paul D, et al.
Publicado: (2022)

Effect of Romosozumab on Trabecular Bone Score Compared to Anti-Resorptive Agents in Postmenopausal Women with Osteoporosis
por: Jeong, Chaiho, et al.
Publicado: (2022)

Profile of romosozumab and its potential in the management of osteoporosis
por: Lim, Sian Yik, et al.
Publicado: (2017)

European guidance for the diagnosis and management of osteoporosis in postmenopausal women
por: Kanis, J. A., et al.
Publicado: (2008)

European guidance for the diagnosis and management of osteoporosis in postmenopausal women
por: Kanis, J. A., et al.
Publicado: (2008)

Romosozumab, clinical trials, and real-world care of patients with osteoporosis
por: Lewiecki, E. Michael
Publicado: (2020)

Romosozumab in Postmenopausal Korean Women with Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study
por: Baek, Ki-Hyun, et al.
Publicado: (2021)

Romosozumab-aqqg in the Treatment of Osteoporosis in a Patient With Hypophosphatasia
por: Khanjee, Naveed, et al.
Publicado: (2022)

Vitiligo progression in a patient undergoing romosozumab treatment for osteoporosis
por: Trepanowski, Nicole, et al.
Publicado: (2023)

Risk for hip fracture before and after total knee replacement in Sweden
por: Vala, C.H., et al.
Publicado: (2019)

European guidance for the diagnosis and management of osteoporosis in postmenopausal women
por: Kanis, J.A., et al.
Publicado: (2018)

Romosozumab: a novel bone anabolic treatment option for osteoporosis?
por: Kerschan-Schindl, Katharina
Publicado: (2019)

Romosozumab for the treatment of osteoporosis in women: Efficacy, safety, and cardiovascular risk
por: Lim, Sian Yik
Publicado: (2022)

Romosozumab versus Teriparatide for the Treatment of Postmenopausal Osteoporosis: A Systematic Review and Meta‐analysis through a Grade Analysis of Evidence
por: Tian, Aixian, et al.
Publicado: (2021)

Correction to: European guidance for the diagnosis and management of osteoporosis in postmenopausal women
por: Kanis, J.A., et al.
Publicado: (2020)

Commentary on guidelines on postmenopausal osteoporosis - Indian Menopause Society
por: Kanis, John
Publicado: (2013)

Clinical Utility of Romosozumab in the Management of Osteoporosis: Focus on Patient Selection and Perspectives
por: Lim, Sian Yik, et al.
Publicado: (2022)

MON-378 Efficacy and Safety of Romosozumab vs Alendronate Is Similar Across Different Levels of Renal Function Among Postmenopausal Women with Osteoporosis
por: Miller, Paul, et al.
Publicado: (2020)

Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active‐Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial
por: Brown, Jacques P., et al.
Publicado: (2021)

Osteoporosis in Europe: a compendium of country-specific reports
por: Willers, Carl, et al.
Publicado: (2022)

SCOPE 2021: a new scorecard for osteoporosis in Europe
por: Kanis, John A., et al.
Publicado: (2021)

Bone‐Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment
por: Chavassieux, Pascale, et al.
Publicado: (2019)

Pregnancy and Lactation-Associated Osteoporosis Successfully Treated with Romosozumab: A Case Report
por: Kaneuchi, Yoichi, et al.
Publicado: (2022)

Osteoporosis Improved by Romosozumab Therapy in a Patient With Type I Osteogenesis Imperfecta
por: Dattagupta, Antara, et al.
Publicado: (2023)

Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients
por: Shimizu, Tomohiro, et al.
Publicado: (2021)

The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden
por: Murphy, Daniel R, et al.
Publicado: (2012)

European guidance for the diagnosis and management of osteoporosis in postmenopausal women
por: Kanis, J. A., et al.
Publicado: (2012)

RF30 | PSAT138 Romosozumab-aqqg in the Treatment of Osteoporosis in a Patient with Hypophosphatasia
por: Khanjee, Naveed, et al.
Publicado: (2022)

A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures
por: Schemitsch, Emil H., et al.
Publicado: (2020)

Impact of spinal cord stimulation on sick leave and disability pension in patients with chronic neuropathic pain: a real-world evidence study in Sweden
por: Söreskog, Emma, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4clcus252vpk1u7dr0jsbch9d9